CORRIGENDUM

Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]

Senbel E, Tropé S, Herman-Demars H, et al. *Patient Prefer Adherence*. 2021;15:751–760.

Page 751, Abstract, Results section, the text “Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even

in patients with unchanged MTX dose” should read “Switch to SC route increased the proportion of patients with remission or LDA from 22.2% to 52.3% and increased quality of life even in patients with unchanged MTX dose”.

The authors apologize for this error.

Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease

states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/patient-preference-and-adherence-journal>

<https://doi.org/10.2147/PPA.S330289>

Received: 20 July 2021
Accepted: 20 July 2021
Published: 27 July 2021

Patient Preference and Adherence 2021:15 1679

© 2021 Senbel et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

1679